



**TMC LIFE SCIENCES BHD**  
**Company no. 624409-A**  
**(Incorporated in Malaysia)**

**INTERIM FINANCIAL REPORT  
FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010**

**Contact**

No 11 Jalan Teknologi  
Taman Sains Selangor 1  
PJU 5, Kota Damansara  
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111  
Fax: +603 6287 1212

[www.tmc.life.com](http://www.tmc.life.com)  
21/11/2010 18:33

[www.tropicana-medicalcentre.com](http://www.tropicana-medicalcentre.com)

**TMC LIFE SCIENCES BHD**  
**Company no. 624409-A**  
**(Incorporated in Malaysia)**

---

**INTERIM FINANCIAL REPORT FOR THE**  
**THIRD QUARTER ENDED 30 SEPTEMBER 2010**

---

**CONDENSED CONSOLIDATED INCOME STATEMENT**

	<u>INDIVIDUAL QUARTER</u>		<u>CUMULATIVE QUARTER</u>	
	Current Quarter Ended 30 Sep 2010 (UNAUDITED) RM	Preceding Year Corresponding Quarter 30 Sep 2009 (UNAUDITED) RM	Current Year To Date 30 Sep 2010 (UNAUDITED) RM	Preceding Year Corresponding Period 30 Sep 2009 (UNAUDITED) RM
Revenue	14,561,120	12,253,116	41,210,044	34,243,338
Operating expenses	(12,919,866)	(11,674,098)	(39,439,745)	(34,113,671)
<b>Profit/(Loss) from operations</b>	<b>1,641,254</b>	<b>579,018</b>	<b>1,770,299</b>	<b>129,667</b>
Amortisation & depreciation	(2,048,242)	(2,092,792)	(6,161,289)	(6,001,963)
Finance costs	(697,351)	(470,283)	(2,003,353)	(1,240,644)
Other operating expenses	(3,331,190)	-	(3,331,190)	-
Interest income	25,227	7,154	55,021	122,486
Share of loss of associate	-	-	(28,262)	-
<b>Loss before taxation</b>	<b>(4,410,302)</b>	<b>(1,976,903)</b>	<b>(9,698,774)</b>	<b>(6,990,454)</b>
Taxation	(709)	(26,896)	(144,145)	(59,820)
<b>Loss after taxation</b>	<b>(4,411,011)</b>	<b>(2,003,799)</b>	<b>(9,842,919)</b>	<b>(7,050,274)</b>
<b>ATTRIBUTABLE TO:</b>				
Equity holders of the Company	(4,388,875)	(1,909,159)	(9,729,248)	(6,752,070)
Minority interests	(22,136)	(94,640)	(113,671)	(298,204)
	<b>(4,411,011)</b>	<b>(2,003,799)</b>	<b>(9,842,919)</b>	<b>(7,050,274)</b>
(Loss) / Earnings per share (sen)				
- Basic	(0.73)	(0.32)	(1.62)	(1.12)
- Diluted	N/A	N/A	N/A	N/A

Note : N/A denotes Not Applicable

The condensed consolidated income statement should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

**TMC LIFE SCIENCES BHD**  
**Company no. 624409-A**  
**(Incorporated in Malaysia)**

---

**INTERIM FINANCIAL REPORT FOR THE**  
**THIRD QUARTER ENDED 30 SEPTEMBER 2010**

---

**CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**

	<u>INDIVIDUAL QUARTER</u>		<u>CUMULATIVE QUARTER</u>	
	Current Quarter Ended 30 Sep 2010 (UNAUDITED) RM	Preceding Year Corresponding Quarter 30 Sep 2009 (UNAUDITED) RM	Current Year To Date 30 Sep 2010 (UNAUDITED) RM	Preceding Year Corresponding Period 30 Sep 2009 (UNAUDITED) RM
Loss after taxation	(4,411,011)	(2,003,799)	(9,842,919)	(7,050,274)
<i>Other comprehensive income/(loss)</i>				
Currency translation differences	<u>42,791</u>	<u>(18,486)</u>	<u>45,199</u>	<u>(6,309)</u>
<b>Total comprehensive loss for the period</b>	<b><u>(4,368,220)</u></b>	<b><u>(2,022,285)</u></b>	<b><u>(9,797,720)</u></b>	<b><u>(7,056,583)</u></b>
<b>Total comprehensive loss attributable to:</b>				
Equity holders of the Company	(4,346,084)	(1,927,645)	(9,684,049)	(6,758,379)
Minority interests	<u>(22,136)</u>	<u>(94,640)</u>	<u>(113,671)</u>	<u>(298,204)</u>
	<b><u>(4,368,220)</u></b>	<b><u>(2,022,285)</u></b>	<b><u>(9,797,720)</u></b>	<b><u>(7,056,583)</u></b>

The condensed consolidated statement of comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

**TMC LIFE SCIENCES BHD**  
**Company no. 624409-A**  
**(Incorporated in Malaysia)**

**INTERIM FINANCIAL REPORT FOR THE**  
**THIRD QUARTER ENDED 30 SEPTEMBER 2010**

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

	AS AT 30 September 2010 (UNAUDITED)	AS AT 31 December 2009 (RESTATED)
Note	RM	RM
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
Property, plant and equipment	132,196,836	135,213,059
Long term trade receivables	1,472,251	-
Goodwill	-	3,331,190
Intangible assets	12,133,902	12,528,472
Investment in associate	337,859	216,121
	<u>146,140,848</u>	<u>151,288,842</u>
<b>Current Assets</b>		
Inventories	3,220,169	3,627,209
Trade receivables	9,150,971	6,358,070
Other receivables, deposits and prepayments	5,948,401	4,703,402
Short-term investments	-	2,510,682
Cash and bank balances	3,553,906	5,263,851
	<u>21,873,447</u>	<u>22,463,214</u>
<b>TOTAL ASSETS</b>	<u><b>168,014,295</b></u>	<u><b>173,752,056</b></u>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity Attributable To Equity Holders Of The Company</b>		
Share capital	60,177,975	60,177,975
Share premium	21,751,724	21,751,724
Foreign exchange reserve	41,982	(3,217)
Retained profits	9,389,906	21,495,335
<b>Total Equity</b>	<u><b>91,361,587</b></u>	<u><b>103,421,817</b></u>
Minority interests	-	114,028
<b>Total Equity Attributable To Equity Holders Of The Company</b>	<u><b>91,361,587</b></u>	<u><b>103,535,845</b></u>
<b>Non-Current Liabilities</b>		
Term loans	42,288,837	40,318,838
Hire purchase	-	413,109
Deferred taxation	3,229,167	3,229,167
	<u><b>45,518,004</b></u>	<u><b>43,961,114</b></u>
<b>Current Liabilities</b>		
Trade payables	9,934,053	5,412,385
Other payables	10,886,914	10,380,197
Term loans	8,347,849	7,678,563
Hire purchase	444,081	112,604
Bank overdraft	1,514,798	2,671,290
Tax payable	7,009	58
	<u><b>31,134,704</b></u>	<u><b>26,255,097</b></u>
<b>TOTAL LIABILITIES</b>	<u><b>76,652,708</b></u>	<u><b>70,216,211</b></u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u><b>168,014,295</b></u>	<u><b>173,752,056</b></u>
<b>NET ASSETS PER TEN SEN ORDINARY SHARE (RM)</b>	<u><b>0.1518</b></u>	<u><b>0.1720</b></u>

The condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

INTERIM FINANCIAL REPORT FOR THE  
THIRD QUARTER ENDED 30 SEPTEMBER 2010

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Share Capital RM	Share Premium RM	Foreign Exchange Translation Reserve RM	Distributable Retained Profits RM	Total RM	Minority Interests RM	Total Equity RM
<b>At 1 January 2010</b>	60,177,975	21,751,724	(3,217)	21,495,335	103,421,817	114,028	103,535,845
Effect of adopting FRS 139	-	-	-	(570,842)	(570,842)	-	(570,842)
As at 1 January 2010, restated	60,177,975	21,751,724	(3,217)	20,924,493	102,850,975	114,028	102,965,003
Total comprehensive loss for the year	-	-	45,199	(9,729,248)	(9,684,049)	(114,028)	(9,798,077)
Dividends paid	-	-	-	(1,805,339)	(1,805,339)	-	(1,805,339)
<b>At 30 September 2010</b>	60,177,975	21,751,724	41,982	9,389,906	91,361,587	-	91,361,587
<b>At 1 January 2009</b>	60,177,975	21,751,724	(23,462)	32,103,833	114,010,070	7,656	114,017,726
Total comprehensive income/(loss) for the year	-	-	20,245	(8,803,159)	(8,782,914)	57,492	(8,725,422)
Shares subscribed by minority shareholders	-	-	-	-	-	48,880	48,880
Dividends paid	-	-	-	(1,805,339)	(1,805,339)	-	(1,805,339)
<b>At 31 December 2009</b>	60,177,975	21,751,724	(3,217)	21,495,335	103,421,817	114,028	103,535,845

The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

**TMC LIFE SCIENCES BHD**  
**Company no. 624409-A**  
**(Incorporated in Malaysia)**

**INTERIM FINANCIAL REPORT FOR THE**  
**THIRD QUARTER ENDED 30 SEPTEMBER 2010**

**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**

	<b>PERIOD ENDED 30 September 2010 RM (UNAUDITED)</b>	<b>PRECEDING YEAR ENDED 31 December 2009 RM (AUDITED)</b>
<b>Cash flows from operating activities</b>		
Loss before taxation	(9,698,774)	(8,797,995)
Adjustments for		
Non-cash items	9,032,787	8,808,790
Gain on disposal of property, plant and equipment	(7,620)	(172,968)
Share of loss/(profit) in associated company	28,262	(736)
Interest paid	2,003,353	1,744,741
Interest income	(55,021)	(151,638)
Operating profit before changes in working capital	<u>1,302,987</u>	<u>1,430,194</u>
(Increased)/Decrease in inventories	407,040	(1,912,019)
(Increased)/Decrease in receivables	(5,621,658)	18,784,292
(Increased)/Decrease in payables	<u>5,028,385</u>	<u>(3,193,516)</u>
Cash generated from operations	1,116,754	15,108,951
Interest paid	(2,003,353)	(1,744,741)
Interest received	55,021	151,638
Income tax paid	(137,194)	(653,743)
<b>Net cash (used in)/generated from operating activities</b>	<u>(968,772)</u>	<u>12,862,105</u>
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(2,742,544)	(44,344,123)
Nurse sponsorship incurred, net of receipts	-	(1,033,877)
Proceeds from disposal of property, plant and equipment	25,650	335,300
Development Costs	(25,982)	-
Investment in associate company	(150,000)	(215,385)
Issuance of subsidiary's ordinary shares	-	48,880
Withdrawal/(Deposit) of short-term investments	<u>2,510,682</u>	<u>(2,498,713)</u>
<b>Net cash used in investing activities</b>	<u>(382,194)</u>	<u>(47,707,918)</u>
<b>Cash flows from financing activities</b>		
Dividends paid	(1,805,339)	(1,805,339)
Proceeds from term loan	5,700,000	23,000,000
Repayment of term loans	(3,060,715)	(5,002,599)
Repayment of hire purchase	(81,632)	(74,287)
<b>Net cash (used in)/ generated from financing activities</b>	<u>752,314</u>	<u>16,117,775</u>
<b>Net decrease in cash and cash equivalents</b>	<b>(598,652)</b>	<b>(18,728,038)</b>
Cash and cash equivalents at beginning of financial period/year	2,592,561	21,302,176
Effects of exchange rate changes on cash and bank balances	45,199	18,423
<b>Cash and cash equivalents at end of financial period/year</b>	<u><u>2,039,108</u></u>	<u><u>2,592,561</u></u>
<b>NOTES TO CASH FLOW STATEMENT</b>		
<b>Cash and cash equivalents comprise:</b>		
Cash and bank balances	3,553,906	5,263,851
Bank overdraft	(1,514,798)	(2,671,290)
<b>Total cash and cash equivalents</b>	<u><u>2,039,108</u></u>	<u><u>2,592,561</u></u>

The condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements for the year ended 31 December 2009 and the accompanying explanatory notes attached to the interim financial statements.

**NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2010**

**A EXPLANATORY NOTES PURSUANT TO FINANCIAL REPORTING STANDARD (“FRS”)**

**A1 BASIS OF PREPARATION**

The interim financial statements have been prepared in accordance with the requirements of Financial Reporting Standards (FRS) 134 "Interim Financial Reporting" and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad for the Main Board.

The interim financial statements should be read in conjunction with the audited financial statements of the Group for the year ended 31 December 2009. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2009.

**A2 CHANGES IN ACCOUNTING POLICIES**

The significant accounting policies adopted are consistent with those of the audited financial statements for the financial year ended 31 December 2009, except for the adoption of the following new Financial Reporting Standards (FRSs) and IC Interpretations with effect from 1 January 2010:

FRS 4	Insurance Contracts
FRS 7	Financial Instruments: Disclosures
FRS 8	Operating Segments
FRS 101	Presentation of Financial Statements (Revised)
FRS 123	Borrowing Costs (Revised)
FRS 132	Financial Instruments: Presentation (Revised)
FRS 139	Financial Instruments: Recognition and Measurement
Amendment to FRS 1	First-time Adoption of Financial Reporting Standard
Amendment to FRS 2	Share-based Payment –Vesting conditions and Cancellations
Amendment to FRS 7	Financial Instruments: Disclosures
Amendment to FRS 8	Operating Segments
Amendment to FRS 107	Statement of Cash Flows
Amendment to FRS 108	Accounting Policies, Changes in Accounting Estimates and Errors
Amendment to FRS 110	Events after the Reporting Period
Amendment to FRS 116	Property, Plant & Equipment
Amendment to FRS 117	Leases
Amendment to FRS 118	Revenue
Amendment to FRS 119	Employee Benefits
Amendment to FRS 127	Consolidated and Separate Financial Statements
Amendment to FRS 132	Financial Instruments: Presentation
Amendment to FRS 134	Interim Financial Reporting
Amendment to FRS 136	Impairment of Assets
Amendment to FRS 138	Intangible Assets
Amendment to FRS 139	Financial Instruments: Recognition and Measurement
IC Interpretation 9	Reassessment of Embedded Derivatives
IC Interpretation 10	Interim Financial Reporting and Impairment

A2 CHANGES IN ACCOUNTING POLICIES (CONT'D)

The principal effects of the changes in presentation, changes in methods of computation and in accounting policies resulting from the adoption of the new and revised FRSs, IC Interpretations and Amendments are set out below:

i) FRS 8: Operating Segments

FRS 8 requires segment information to be presented on a similar basis to that used for internal reporting purposes. A review of the Group's reportable segment concluded that the Group is primarily engaged in one operating segment namely, the healthcare sector. This conclusion is consistent with the financial information regularly reviewed by the Group's chief operating decision maker who makes decisions on the allocation of resources and assesses the performance of the Group. This standard does not have any impact on the financial position and results of the Group.

ii) FRS 101 : Presentation of Financial Statements

The FRS 101 introduces the statement of comprehensive income: presenting all items of income and expense recognized in the income statement, together with all the other items of recognized income and expense, either in one single statement, or in two linked statement. In addition, a statement of financial position is required at the beginning of the earliest comparative period following a change in accounting policy, the correction of an error or the reclassification of items in the financial statement. Comparative information, with exception of the requirements under FRS 139, have been re-presented to be in conformity with the revised standard. The FRS did not have any impact on the financial position and results of the Group.

iii) FRS 117 : Leases

The amendments requires entity with existing leases of land and building to reassess the classification of land as finance or operating lease. Following the amendments, the Group has reclassified the existing leasehold land to property, plant and equipment, with no effect on reported profit or equity. However, as a result of the adoption of the amendments, comparative balances as at 31 December 2009 has been restated as follows:

	As previously reported	Effect of adopting amendments to FRS117	As restated
	RM	RM	RM
Property, plant and equipment	116,429,729	18,783,330	135,213,059
Prepaid land lease payments	18,783,330	(18,783,330)	-

iv) FRS 139 : Financial Instruments : Recognition and Measurement

The FRS 139 establishes principles for recognizing and measuring financial assets, financial liabilities and some contracts to buy and sell non-financial items. This FRS did not have any significant impact on the financial position and results of the Group

**Impact on opening balance**

In accordance with the transitional provisions of FRS139, the changes are applied prospectively and the comparative as at 31 December 2009 are not restated. Instead, the changes have been accounted for by restating the following opening balances in the Statement of Financial Position as at 1 January 2010.



iv) FRS 139 : Financial Instruments : Recognition and Measurement (cont'd)

		<b>Previously stated</b>	<b>Effect of FRS139</b>	<b>As restated</b>
		<b>RM</b>	<b>RM</b>	<b>RM</b>
<b>Assets</b>				
Long term receivables		-	1,472,251	1,472,251
Trade receivables		6,358,070	(2,043,092)	4,314,978
<b>Equity</b>				
Retained earnings		21,495,335	(570,842)	20,924,493

A3 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

There were no audit qualifications in the annual financial statements of the Company and its subsidiaries for the financial year ended 31 December 2009.

A4 SEASONALITY OR CYCLICALITY OF OPERATIONS

The business of the Group is not significantly affected by any seasonal or cyclical factors.

A5 UNUSUAL ITEMS

During the current quarter under review, the Group recognized an impairment loss on its goodwill on consolidation of RM3,331,190.

Other than the above, there were no items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A6 CHANGE IN ESTIMATES

There were no material changes in the nature and amount of estimates reported that have a material effect in the current financial period under review.

A7 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial period under review.

A8 VALUATION OF PROPERTY, PLANT AND EQUIPMENT

There was no revaluation on any of the Group's property, plant and equipment during the current financial period under review.

A9 DIVIDENDS PAID

A first and final single-tier tax exempt dividend of 3% per ordinary share of RM0.10 each amounting to RM1,805,339 for the financial year ended 31 December 2009 was approved on 18 June 2010 and paid on 28 July 2010.

**A10 SEGMENTAL INFORMATION**

The Group operates mainly in Malaysia and currently is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital. The Group also provides fertility and gynecological services, stem cell banking and therapy, and research and development in life sciences.

**A11 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD**

There were no material events subsequent to 31 December 2009 and up to the date of this report.

**A12 CHANGES IN THE COMPOSITION OF THE GROUP**

There were no changes in the composition of the Group during the current financial period under review other than disclosed below.

On 1 June 2010, the Company subscribed for 150,000 ordinary shares of RM1.00 each in its associated company, Academy of Nursing (M) Sdn. Bhd. by way of Rights Issue at an issue price of RM1.00 each on the basis of four (4) new ordinary shares for every one (1) existing ordinary share held, at a total consideration of RM150,000 and renounced its rights on the remaining 10,000 ordinary shares of RM1.00 each.

On 18 June 2010, the Company disposed of 15 (fifteen) ordinary shares of RM1.00 each representing 15% of the issued and paid-up capital in its wholly-owned subsidiary, Tropicana Medical Centre (Penang) Sdn. Bhd. for a total consideration of RM735,176 to its wholly-owned subsidiary, TMC Women's Specialist Holdings Sdn. Bhd.

**A13 CONTINGENT LIABILITIES OR CONTINGENT ASSETS**

The Company has provided corporate guarantees to licensed financial institutions for banking facilities, and suppliers amounting to RM65.887 million and RM1.6 million respectively. The guarantees were granted for the benefit of the Company's subsidiaries and associated company. The banking facilities are primarily for financing the construction and equipping of the Group's flagship hospital, and a proportionate guarantee for hire purchase facility granted to its associated company. Arising from this, the Company is contingently liable for the amount utilized by its subsidiaries and associated company of approximately RM52.7 million as at 30 September 2010.

**A14 CAPITAL COMMITMENTS**

Capital expenditures not provided for in the interim financial report as at 30 September 2010 are as follows:

	<b>RM '000</b>
Approved and contracted for	4,141
Approved but not contracted for	-
	4,141

**A15 SIGNIFICANT RELATED PARTY TRANSACTIONS**

There are no significant related party transactions during the current financial period under review.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD  
("BURSA SECURITIES")**

**B1 REVIEW OF PERFORMANCE**

The Group recorded revenue of RM14.56 million and RM41.21 million for the current quarter and financial year to date respectively, reflecting an increase of 18.86% and 20.36% respectively as compared to RM12.25 million and RM34.24 million for the corresponding periods in the previous year. The improvement was mainly due to the increased revenues from the Group's flagship multi disciplinary tertiary hospital, operating with more comprehensive services during the periods under review than were offered in corresponding periods in the previous year. In addition, promotional activities of the hospital during the financial year ended 31 December 2009 contributed to the market awareness of the hospital.

The improvement in operations however, was exacerbated by the impairment loss on goodwill on consolidation recognized in the current quarter under review which amounted to RM3.33 million. This resulted in a loss after taxation and minority interest of RM4.39 million and RM9.73 million for the current quarter and financial year to date respectively, an increase of 129.89% and 44.15% as compared to RM1.91 million and RM6.75 million for the corresponding periods in the previous year.

The impairment loss on goodwill is in respect of the Company's investment in Tropicana Medical Centre (Penang) Sdn. Bhd.. Excluding the effect of this item, the Group would have achieved a loss after taxation and minority interest of RM1.06 million and RM6.40 million for the current quarter and financial year to date respectively, showing an improvement of 44.50% and 5.19% as compared to the corresponding periods in the previous year.

**B2 COMPARISON WITH PRECEDING QUARTER'S RESULTS**

The Group recorded a revenue and loss before taxation of RM14.56 million and RM4.41 million respectively for the current quarter as compared to a revenue of RM14.28 million and loss before taxation of RM2.69 million in the preceding quarter.

If not for the impairment loss on goodwill amounting to RM3.33 million on consolidation, the loss before taxation for the current quarter would have narrowed to RM1.08 million, an improvement of 59.85% as compared to the preceding quarter.

**B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 31 DECEMBER 2010**

The Board is positive that the Group's revenue base will continue to increase in FY2010, spurred by the increased number of specialist doctors and support personnel at the flagship hospital, as well as ongoing promotional activities of the hospital's advanced facilities and services. In addition, the Group's other fertility centres, wellness program, and stem cell services will continue to contribute to the Group's revenue. The Board will endeavour to improve the operational efficiency of the Group.

**B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE**

Not applicable.

B5 TAXATION

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	QUARTER ENDED	QUARTER ENDED	PERIOD ENDED	PERIOD ENDED
	30 Sep 2010	30 Sep 2009	30 Sep 2010	30 Sep 2009
Malaysian income tax:				
- current taxation	(709)	(26,896)	(144,145)	(59,820)
- prior year taxation	-	-	-	-
- deferred taxation	-	-	-	-
<b>Total</b>	<b>(709)</b>	<b>(26,896)</b>	<b>(144,145)</b>	<b>(59,820)</b>

The effective tax rate was higher than the statutory income tax rate in Malaysia due to the losses of certain subsidiaries that were not available for set off against taxable profits of other subsidiaries and certain expenses which were not deductible for tax purposes.

B6 PROFIT ON SALE OF UNQUOTED INVESTMENTS AND/OR PROPERTIES

There were no sale of unquoted investments and/or properties during the current financial period under review.

B7 QUOTED SECURITIES

There were no purchases or disposals of quoted securities during the current financial period under review.

B8 SIGNIFICANT EVENT

There was no significant event in the quarter under review.

B9 STATUS OF CORPORATE PROPOSAL

There were no corporate proposals in this quarter except the following:

On 18 September 2008, the Company entered into a Memorandum of Understanding with Berjaya Corporation Berhad and Viet Ha Corporation to establish a formal relationship in order to jointly carry out activities relating to the design, construction, furnishing, equipping and operating of a hospital in or near Hanoi, Vietnam.

Further to the announcement made on 18 September 2008, on 17 September 2009 the parties to the Memorandum of Understanding (MOU) have mutually agreed to extend the duration of the MOU for a further period of twelve (12) months from 17 September 2009 until 17 September 2010.

On 17 September 2010, the Company announced that the parties to the MOU have mutually extended the duration of the MOU for a further period of twelve (12) months from 17 September 2010 until 17 September 2011.

**B10 BORROWINGS**

The Group's borrowings as at 30 September 2010 are as follows:-

	Long Term (RM million)	Short Term (RM million)	Total (RM million)
Secured	42.28	10.30	52.58
Unsecured	-	-	-
<b>Total</b>	<b>42.28</b>	<b>10.30</b>	<b>52.58</b>

**B11 OFF BALANCE SHEET FINANCIAL INSTRUMENTS**

There were no off balance sheet financial instruments as at the date of this report.

**B12 MATERIAL LITIGATION**

There were no material litigations as at the date of this report.

**B13 DIVIDENDS**

The Board does not recommend the payment of any dividend for the current financial period under review.

**B14 EARNINGS PER SHARE**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	QUARTER ENDED	QUARTER ENDED	PERIOD ENDED	PERIOD ENDED
<b>Basic earnings per share (EPS)</b>	30 Sep 2010	30 Sep 2009	30 Sep 2010	30 Sep 2009
Net (loss) / profit attributable to shareholders	(4,388,875)	(1,909,159)	(9,729,248)	(6,752,070)
Weighted average number of ordinary shares in issue ('000)	601,780	601,780	601,780	601,780
<b>(LPS)/EPS (sen) - Basic</b>	<b>(0.73)</b>	<b>(0.32)</b>	<b>(1.62)</b>	<b>(1.12)</b>
<b>- Diluted</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>